Mirum Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $120.2M | $31.3M |
| FY2022 | — | $142.0M | $28.0M |
| FY2023 | — | $248.7M | $286.3M |
| FY2024 | — | $225.6M | $222.5M |
| FY2025 | — | $314.7M | $296.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $120.2M | $31.3M |
| FY2022 | — | $142.0M | $28.0M |
| FY2023 | — | $248.7M | $286.3M |
| FY2024 | — | $225.6M | $222.5M |
| FY2025 | — | $314.7M | $296.7M |